Business Standard

Syrup deaths in Uzbekistan: Pharmexcil suspends Marion Biotech's membership

Co grew rapidly in the last four-five years; primarily makes cold medication

cough syrup, medicine, cold
Premium

File photo of cough syrup. Photo: Shutterstock

Sohini Das Mumbai
In the wake of the controversy surrounding Noida-based Marion Biotech about its medicine for cough and cold allegedly being linked to the deaths of 18 children in Uzbekistan, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) on Friday suspended the membership of the company with immediate effect.

The company will thus be ineligible for incentives under the Market Access Initiative Scheme.

Meanwhile, the data sourced from Tofler shows the Noida-based firm, promoted by Sachin Jain, has seen strong growth in revenues and profitability in the past four-five years.

It posted operating revenues of Rs 93.11 crore in FY22, with

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in